Cybin Inc. (HELP)
NASDAQ: HELP · Real-Time Price · USD
11.78
+0.11 (0.94%)
At close: Aug 19, 2026, 4:00 PM EDT
11.98
+0.20 (1.68%)
After-hours: Aug 19, 2026, 7:55 PM EDT
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
730.17M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 174.48M |
| Gyre Therapeutics | 109.82M |
| 4D Molecular Therapeutics | 92.01M |
| CytomX Therapeutics | 18.30M |
| Crescent Biopharma | 11.88M |
| Allogene Therapeutics | 4.64M |
| Shattuck Labs | 1.00M |
| Neurogene | 925.00K |
HELP News
- 1 day ago - Helus Pharma appoints Regina Donohue as chief people officer - TheFly
- 1 day ago - Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board - GlobeNewsWire
- 5 days ago - Cybin Earnings release: Q1 2027 - Filings
- 5 days ago - Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 days ago - Cybin Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 14 days ago - Helus Pharma appoints Michael Halstead as CEO - TheFly
- 16 days ago - Helus Pharma Appoints Michael Halstead as Chief Executive Officer - GlobeNewsWire
- 23 days ago - Helus Pharma initiated with an Overweight at Wells Fargo - TheFly